What is the official website of NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company ?

The official website of NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is http://www.nutrichem.de.

What is NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company's cybersecurity risk score?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company experienced?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company been affected by any supply chain cyber incidents ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have SOC 2 Type 1 certification ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is not certified under SOC 2 Type 1.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have SOC 2 Type 2 certification ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company does not hold a SOC 2 Type 2 certification.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company comply with GDPR ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is not listed as GDPR compliant.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have PCI DSS certification ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company does not currently maintain PCI DSS compliance.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company comply with HIPAA ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is not compliant with HIPAA regulations.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have ISO 27001 certification ?

According to Rankiteo,NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company operate in ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company employs approximately 73 people worldwide.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company own any subsidiaries ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company presently has no subsidiaries across any sectors.

How many LinkedIn followers does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company's official LinkedIn profile has approximately 2,193 followers.

What is the NAICS classification code for NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have a Crunchbase profile ?

No, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company does not have a profile on Crunchbase.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have a LinkedIn profile ?

Yes, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/nutrichem-de.

How many cybersecurity incidents has NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company experienced ?

As of August 1, 2026, Rankiteo reports that NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company has not experienced any cybersecurity incidents.

How many peer or competitor companies does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company has an estimated 5,720 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

NDPGBBC

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company Vendor Cyber Rating & Cyber Score

nutrichem.de

Add Your Compliance Badge

NUTRICHEM DIÄT + PHARMA GMBH and its subsidiary inkospor® are part of the B. Braun Group of companies. NUTRICHEM DIÄT + PHARMA GMBH develops, manufactures, and packages high-quality nutritional and pharmaceutical products with state-of-the-art technology for clients across the globe. Backed by a powerhouse R&D department, we help our clients manufacture nutritional products in the areas of: -Enteral Nutrition -OEM -Sports Nutrition NUTRICHEM had its early roots in the raw materials industry in 1977 and over the years has developed into a major food manufacturer in Germany that has penetrated beyond clinical nutrition into the world of sports nutrition. Over the years, NUTRICHEM was taken over by B. Braun Melsungen AG in order to

NDPGBBC A.I CyberSecurity Scoring

Scoring History

NDPGBBC

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

NDPGBBC Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for NDPGBBC

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company in 2026.

Incident Types NDPGBBC vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company in 2026.

Incident History - NDPGBBC (X = Date, Y = Severity)

Loading…

SUBSIDIARY

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company Subsidiaries

NDPGBBC

Pharmaceutical Manufacturing

Website: http://www.nutrichem.de

Company Size: 201-500 employees

B. Braun GroupMedical Equipment Manufacturing

B. Braun Medical Inc. (US)Medical Equipment Manufacturing

B. Braun New VenturesMedical Equipment Manufacturing

B. Braun Vet CareTierärztliche Leistungen

Aesculap AcademyEducation

Loading…

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company Similar Companies

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Loading…

NEWS

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-9044

SUMMARY

An OS command injection vulnerability exists in the VPN module of TP-Link AXE75 V1 routers. This vulnerability allows an adjacent, authenticated attacker to execute arbitrary commands on the device by importing a specially crafted VPN client configuration file. The issue arises from improper filtering of special characters. Successful exploitation of this vulnerability may enable an attacker to gain full control of the affected device, potentially compromising configuration integrity, network security, and service availability.

Published

Date2026-07-31

Updated

Date2026-07-31

RISK INFORMATION (Score: )

cvss4

Base Score: 8.5

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:H/UI:N/VC:H/VI:H/VA:H/SC:L/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-54909

SUMMARY

pion/stun is a Go implementation of STUN. Prior to 3.1.3, XORMappedAddress.GetFromAs can panic while parsing a malformed short XOR-MAPPED-ADDRESS attribute in STUN or ICE Binding-response parsing paths, allowing remote denial of service. This issue is fixed in version 3.1.3.

Published

Date2026-07-31

Updated

Date2026-07-31

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-54785

SUMMARY

gemini-bridge is a lightweight MCP server bridging AI agents to Google's Gemini AI via the official CLI. From 1.0.0 until 1.3.1, consult_gemini_with_files in inline mode read any file path supplied in the files argument without confining it to the working directory, then forwarded the contents to the Gemini CLI. Because the caller also controls query, the file contents are echoed back through the Gemini round-trip (and sent to Google), making this an arbitrary local file read. This issue is fixed in version 1.3.1.

Published

Date2026-07-31

Updated

Date2026-07-31

RISK INFORMATION (Score: 6.2)

cvss3

Base Score: 6.2

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.5

REFERENCES

CVE-2026-54768

SUMMARY

WPGraphQL provides a GraphQL API for WordPress sites. From 2.0.0 until 2.15.1, the deprecated user field on SendPasswordResetEmailPayload lets an unauthenticated caller distinguish existing author-class accounts through the sendPasswordResetEmail mutation and obtain public profile fields. This issue is fixed in version 2.15.1.

Published

Date2026-07-31

Updated

Date2026-07-31

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-53573

SUMMARY

GeoNetwork is a catalog application to manage spatially referenced resources. From 3.12.0 until 4.2.16 and 4.4.11, unsafe redirect validation in GeonetworkOAuth2LoginAuthenticationFilter and KeycloakAuthenticationProcessingFilter permits an attacker-controlled external redirect after login. This issue is fixed in versions 4.2.16 and 4.4.11.

Published

Date2026-07-31

Updated

Date2026-07-31

RISK INFORMATION (Score: )

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:A/VC:N/VI:N/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…